"How much is Sculptra" draws more than 16,000 US searches a month across its phrasings (clickstream estimate, October 2026), and the answers on clinic pages are prices for that clinic. This page sets out what can be checked instead: the national fee surveys that once reported a Sculptra figure, how many sessions and vials the trials FDA reviewed actually used, why the product is priced per vial, and the single use Medicare pays for. It was checked on 11 October 2026. It is not a price quote and not a recommendation. Whether Sculptra suits a person, and how much of it, is a decision for a qualified clinician.
The published national fees, 2014–2019
The Aesthetic Society (formerly the American Society for Aesthetic Plastic Surgery) published an average physician fee per procedure for Sculptra in its annual databank reports until 2019. We read each year's report:
| Year | Sculptra (PLLA) | Radiesse (CaHA) | Hyaluronic-acid filler |
|---|---|---|---|
| 2014 | $837 | $634 | — |
| 2015 | $782 | $651 | — |
| 2016 | $923 | $698 | — |
| 2017 | $875 | $697 | — |
| 2018 | $985 | $727 | — |
| 2019 | $850 | $705 | $625 |
Three things limit what the table says. The figures are physician fees only — the report excludes facility charges and other costs — and the society notes they reflect "typical fees for one site". They are per procedure, meaning one session, while the same reports list "2–4" treatments for Sculptra. And they are old: the society's 2020 to 2023 reports, which we also opened, carry no fee table for injectables at all, and the American Society of Plastic Surgeons' 2025 report states that it is "seeking a data source" for minimally invasive treatments and ranks them by volume rather than counting or pricing them. No national survey we found has published a Sculptra fee since 2019.
Our arithmetic, not a published figure: at the 2019 average, two to four sessions come to $1,700 to $3,400 in physician fees, in 2019 dollars. That range describes the survey's averages, not what any clinic charges today.
How many sessions and vials the trials used
FDA's Summaries of Safety and Effectiveness Data report how much Sculptra the approval trials used, which is the only standardised record of quantity:
| Trial | Sessions | Quantity |
|---|---|---|
| Nasolabial folds, 2009 approval (P030050/S002) | 116 people had 370 sessions — a mean of about 3.2 (our arithmetic); 116, 110, 85 and 59 people had a first, second, third and fourth session | mean total of 11.7 mL injected per person |
| Cheek wrinkles, 2023 approval (P030050/S039) | mean 3.6 sessions (range 1–4), a month apart | 334 of 345 sessions used one vial and 11 used two — about 3.7 vials per person across the 97 treated (our arithmetic) |
The two trials prepared the product differently: the 2009 label called for 5 mL of sterile water per vial, and the 2023 summary allows 5 or 8 mL. Larger dilutions used off the face are a different preparation again, which our page on Sculptra on the buttocks sets out with the vial counts its studies report. The session design itself — why the trials used a series rather than one appointment — is covered in our Sculptra explainer.
Why Sculptra is priced per vial
FDA's 2023 summary describes Sculptra as a 367.5 mg dose vial of poly-L-lactic acid microparticles with carboxymethylcellulose and mannitol, supplied as a sterile dry powder and sold in packages of two vials. Each vial is mixed with sterile water before use, so the quantity used in a session is counted in vials rather than in prefilled syringes, as with a hyaluronic-acid filler. A clinic quoting "per vial" is quoting in the unit the product is supplied in; a clinic quoting "per session" has folded the vial count into its own price. The two cannot be compared without knowing how many vials a session includes.
That is also why the vial question sits under so many cost searches. The published answer is the trial record above: one vial per session in almost every session of the cheek trial. It is a description of a study, not a guide to what any person will be offered.
Sculptra against other fillers on price
On the one national survey that broke the figures out, a Sculptra session cost more than either alternative in every year from 2014 to 2019: in 2019, $850 against $705 for Radiesse and $625 for a hyaluronic-acid filler. A session fee is only half of the comparison, because the products are used in different numbers of sessions and have different approved uses; the material differences are laid out in Sculptra vs Radiesse.
The only published studies that compare total costs come from HIV-related facial fat loss, not cosmetic use:
- A Madrid trial of 147 people treated with Sculptra, Radiesse, a polyacrylamide gel or their own fat, followed for 24 months, found no significant difference in the number of sessions or volume, but fat grafting cost significantly less than all three synthetic fillers (Vallejo 2018).
- A Canadian cost-utility model, using prices from distributors and physicians in 2009, estimated CAD 57,352 per quality-adjusted life year for poly-L-lactic acid against CAD 45,457 for a polyalkylimide gel, from the provincial health ministry's perspective, and concluded the gel was more cost-effective (Peyasantiwong 2010).
Neither study tells a cosmetic patient what Sculptra costs today. A PubMed search on 11 October 2026 for poly-L-lactic acid or Sculptra with cost terms and a filler or cosmetic context returned 15 records; these two are the only ones that measure the cost of treatment.
What Medicare and insurance cover
Medicare's National Coverage Determination 250.5, effective 23 March 2010, covers dermal injections for facial lipodystrophy syndrome only with fillers FDA has approved for that purpose, and only in people with HIV whose facial fat loss from antiretroviral treatment "is a significant contributor to their depression". Every other use is listed as nationally non-covered. Sculptra's first FDA approval, in 2004, was for exactly this condition.
Two billing codes go with it: G0429, the injection procedure for facial lipodystrophy (from 23 March 2010), and Q2028, "Injection, sculptra, 0.5 mg" (from 1 January 2014), alongside Radiesse's Q2026, billed per 0.1 mL. Q2028 does not appear in CMS's national payment-limit file for October to December 2026, which we searched; payment for it is set by the local Medicare contractor rather than nationally. Cosmetic use falls outside this coverage, and private insurers set their own rules.
What is and is not established
Established: the last published national average physician fee for a Sculptra session was $850 (2019), and it ran higher per session than Radiesse or a hyaluronic-acid filler in each year from 2014 to 2019; the approval trials used about three to four sessions, almost always one vial each in the 2023 trial; Sculptra is supplied as single vials sold in pairs; Medicare covers it only for HIV-related facial fat loss with depression.
Not established: what Sculptra costs today in any given city, since no national survey has published a figure since 2019; whether its longer course makes it cheaper or dearer than fillers over time for cosmetic use; and how many vials any individual needs. Prices, and the number of vials included in them, are worth asking about directly and in writing before a first session.
Sources
- The Aesthetic Society. Aesthetic Plastic Surgery National Databank Statistics, 2014, 2015, 2016, 2017, 2018 and 2019 (national average physician fees, nonsurgical tables); 2020, 2021, 2022 and 2023 reports checked for an injectables fee table (none). PDFs at cdn.theaestheticsociety.org/media/statistics/, read 2026-10-11.
- American Society of Plastic Surgeons. 2025 Plastic Surgery Statistics Report (plasticsurgery.org), read 2026-10-11: minimally invasive treatments presented by volume, no fees.
- US FDA. Summary of Safety and Effectiveness Data, Sculptra Aesthetic, PMA P030050/S002 (nasolabial folds; Table 7, sessions and volumes) and P030050/S039 (cheek wrinkles; device description, Table 4 vials per session), accessdata.fda.gov, read 2026-10-11.
- Centers for Medicare & Medicaid Services. National Coverage Determination 250.5, Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS), effective 2010-03-23, read via the CMS coverage API 2026-10-11. October 2026 Medicare Part B Payment Limit File (effective 2026-10-01 to 2026-12-31), searched for Q2026/Q2028 2026-10-11. HCPCS Q2028, Q2026 and G0429 descriptors and effective dates via the NLM Clinical Tables HCPCS service, 2026-10-11.
- Vallejo A, Garcia-Ruano AA, Pinilla C, et al. Comparing efficacy and costs of four facial fillers in human immunodeficiency virus-associated lipodystrophy: a clinical trial. Plast Reconstr Surg 2018;141(3):613-23. PMID 29135895.
- Peyasantiwong S, Loutfy MR, Laporte A, Coyte PC. An economic evaluation of treatments for HIV-associated facial lipoatrophy: a cost-utility analysis. Curr HIV Res 2010;8(5):386-95. PMID 20426758.
- PubMed E-utilities search, 2026-10-11:
("poly-L-lactic acid"[tiab] OR sculptra[tiab]) AND (cost[tiab] OR costs[tiab] OR price[tiab] OR "cost-effectiveness"[tiab]) AND (filler*[tiab] OR lipoatrophy[tiab] OR aesthetic*[tiab] OR cosmetic*[tiab] OR injectable*[tiab])— 15 records, titles read.